רווח למניה בשנים עשר החודשים האחרונים: Protara Therapeutics Inc (TARA)

Reliance on external partners for clinical trials minimizes operational risks, which is reflected in the earnings per share over the last four quarters on the GURU.Markets terminal linear chart, where -1.38 records a new level. Profit growth is based on the market launch of therapies for rare pathologies, while its status as a reputable developer of innovative oncology treatments strengthens the market position of Protara Therapeutics (TARA).

For Protara Therapeutics (TARA), which focuses on therapies for rare oncological diseases, the 12-month rolling income per share reflects the efficiency of clinical program management through the lens of net profit per share. This metric is calculated by dividing the total annual net income by the number of shares outstanding, allowing investors to differentiate sustainable business growth from short-term reductions in operating expenses.